70,470 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC bought a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 70,470 shares of the biopharmaceutical company's stock, valued at approximately $2,206,000.

Several other hedge funds also recently bought and sold shares of the company. Qube Research & Technologies Ltd raised its position in shares of ACADIA Pharmaceuticals by 757.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 212,919 shares of the biopharmaceutical company's stock valued at $4,437,000 after buying an additional 188,080 shares in the last quarter. RTW Investments LP raised its position in shares of ACADIA Pharmaceuticals by 18.3% during the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company's stock valued at $241,255,000 after buying an additional 1,793,288 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of ACADIA Pharmaceuticals by 9.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,073,093 shares of the biopharmaceutical company's stock valued at $22,363,000 after buying an additional 91,641 shares in the last quarter. Northern Trust Corp raised its position in shares of ACADIA Pharmaceuticals by 4.9% during the 3rd quarter. Northern Trust Corp now owns 1,220,677 shares of the biopharmaceutical company's stock valued at $25,439,000 after buying an additional 57,555 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of ACADIA Pharmaceuticals by 1,284.6% during the 3rd quarter. SG Americas Securities LLC now owns 72,455 shares of the biopharmaceutical company's stock valued at $1,510,000 after buying an additional 67,222 shares in the last quarter. Institutional investors own 96.71% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Robert W. Baird assumed coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, January 30th. They set an "outperform" rating and a $40.00 target price on the stock. Morgan Stanley reduced their price objective on shares of ACADIA Pharmaceuticals from $40.00 to $30.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 13th. JPMorgan Chase & Co. reduced their price objective on shares of ACADIA Pharmaceuticals from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, March 25th. JMP Securities reissued a "market outperform" rating and issued a $42.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 7th. Finally, Royal Bank of Canada reduced their price objective on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.82.

Insider Activity

In other news, insider James Kihara sold 1,790 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.87, for a total transaction of $31,987.30. Following the transaction, the insider now directly owns 13,100 shares in the company, valued at $234,097. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider James Kihara sold 1,790 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.87, for a total transaction of $31,987.30. Following the transaction, the insider now directly owns 13,100 shares in the company, valued at $234,097. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Stephen Davis sold 5,577 shares of the firm's stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $24.67, for a total transaction of $137,584.59. Following the completion of the sale, the chief executive officer now owns 101,890 shares of the company's stock, valued at $2,513,626.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,383 shares of company stock worth $1,291,362. Corporate insiders own 27.50% of the company's stock.

ACADIA Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ ACAD traded down $0.25 during midday trading on Friday, reaching $16.82. 3,628,011 shares of the company's stock traded hands, compared to its average volume of 1,285,911. The stock's 50 day simple moving average is $20.84 and its 200-day simple moving average is $23.75. ACADIA Pharmaceuticals Inc. has a one year low of $16.60 and a one year high of $33.99. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -44.26 and a beta of 0.37.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. The business had revenue of $231.04 million for the quarter, compared to the consensus estimate of $223.79 million. During the same quarter in the prior year, the business posted ($0.26) earnings per share. ACADIA Pharmaceuticals's revenue for the quarter was up 69.3% on a year-over-year basis. Equities analysts predict that ACADIA Pharmaceuticals Inc. will post 0.62 EPS for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.